Today Dewpoint Therapeutics announced a collaboration deal with Bayer, around discovering drugs for cardiovascular and gynecological indications. Less than a year old, Dewpoint is working on applying the young but very promising field of biomolecular condensates to reshape how drugs are made.
We are thrilled to have Bayer recognize the promise of this approach — and can’t help but recognize a positive pattern. Dewpoint is the second Polaris-created company in two weeks to announce a meaningful partnership with pharma, following the Pandion-Astellas collaboration introduced late last month. The two are partnering on treatments for pancreatic autoimmune disease (such as Type 1 diabetes), harnessing Pandion’s breakthrough approach in suppressing the immune system locally through carefully engineered bispecific antibodies.
Both Pandion and Dewpoint were founded on great science applied to a major need in medicine and brought to life by experienced, talented teams. Engaging early with pharma to advance platform technologies is something we deeply believe in, and we are encouraged by the partnerships that Polaris portfolio companies like Dewpoint, Pandion, and many others have forged with big pharma.
Congratulations to the teams!
The Fine Print
This is not an advertisement and should not be construed as an offer of investment advisory services by Polaris Partners or an affiliate thereof or a solicitation or an offer of interests in any private fund sponsored by Polaris Partners or an affiliate thereof (collectively “Polaris Partners”). The views expressed above are educational in nature and do not constitute investment advice. To the extent companies are mentioned, they have been selected by the author on an objective basis to illustrate views expressed in the commentary and do not represent all recommendations for advisory clients. Please visit https://www.polarispartners.com for more information.